Details
Stereochemistry | ACHIRAL |
Molecular Formula | C2H6O3S2 |
Molecular Weight | 142.197 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OS(=O)(=O)CCS
InChI
InChIKey=ZNEWHQLOPFWXOF-UHFFFAOYSA-N
InChI=1S/C2H6O3S2/c3-7(4,5)2-1-6/h6H,1-2H2,(H,3,4,5)
DescriptionCurator's Comment: description was created based on several sources, including:
http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8c79a07d-32cc-4fe7-9a74-152c169f1c4f
http://www.drugbank.ca/drugs/DB09110
https://en.wikipedia.org/wiki/Mesna
Curator's Comment: description was created based on several sources, including:
http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8c79a07d-32cc-4fe7-9a74-152c169f1c4f
http://www.drugbank.ca/drugs/DB09110
https://en.wikipedia.org/wiki/Mesna
Mesna is an organosulfur compound used as an adjuvant in cancer chemotherapy involving cyclophosphamide and ifosfamide. No clinical drug interaction studies have been conducted with mesna. Mesna concentrates in the bladder where acrolein accumulates after administration of chemotherapy and through a Michael addition, forms a conjugate with acrolein and other urotoxic metabolites. This conjugation reaction inactivates the urotoxic compounds to harmless metabolites. The most common adverse reactions (> 10%) when MESNEX is given with ifosfamide are nausea, vomiting, constipation, leukopenia, fatigue, fever, anorexia, thrombocytopenia, anemia, granulocytopenia, diarrhea, asthenia, abdominal pain, headache, alopecia, and somnolence.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL721: Aerolein |
|||
Target ID: CHEMBL733: 4-Hydroxyifosfamide |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Secondary | MESNEX Approved UseMesna Injection is indicated as a prophylactic agent in reducing the incidence of ifosfamide-induced hemorrhagic cystitis. Limitation of Use: Mesna Injection is not indicated to reduce the risk of hematuria due to other pathological conditions such as thrombocytopenia. Mesna Injection is a cytoprotective agent indicated as a prophylactic agent in reducing the incidence of ifosfamide-induced hemorrhagic cystitis. (1) Limitation of Use: Mesna Injection is not indicated to reduce the risk of hematuria due to other pathological conditions such as thrombocytopenia. (1) Launch Date5.9944318E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
33 μM EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/8462128 |
1.2 g single, oral dose: 1.2 g route of administration: Oral experiment type: SINGLE co-administered: |
MESNA blood | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
511 μM EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/8462128 |
1.2 g single, intravenous dose: 1.2 g route of administration: Intravenous experiment type: SINGLE co-administered: |
MESNA blood | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
79 μM EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/9469350 |
0.24 g/m² single, intravenous dose: 0.24 g/m² route of administration: Intravenous experiment type: SINGLE co-administered: |
MESNA blood | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
110 μM × h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/8462128 |
1.2 g single, oral dose: 1.2 g route of administration: Oral experiment type: SINGLE co-administered: |
MESNA blood | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
201 μM × h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/8462128 |
1.2 g single, intravenous dose: 1.2 g route of administration: Intravenous experiment type: SINGLE co-administered: |
MESNA blood | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
49 μM × h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/9469350 |
0.24 g/m² single, intravenous dose: 0.24 g/m² route of administration: Intravenous experiment type: SINGLE co-administered: |
MESNA blood | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
92 min EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/9469350 |
0.24 g/m² single, intravenous dose: 0.24 g/m² route of administration: Intravenous experiment type: SINGLE co-administered: |
MESNA blood | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
Other AEs: Headache, Hypoaesthesia... Other AEs: Headache (43.8%) Sources: Hypoaesthesia (0%) Malaise (0%) Myalgia (0%) Nausea (0%) Pharyngitis (0%) Somnolence (6.3%) Upper respiratory infection (0%) Vomiting (0%) Dizziness (6.3%) Abdominal pain (6.3%) Coughing (0%) Diarrhea (6.3%) Anorexia (0%) Flushing (12.5%) Injection site reaction (12.5%) Back pain (6.3%) Dyspepsia (12.5%) Paraesthesia (6.3%) Renal pain (6.3%) Rigors (12.5%) Fatigue (0%) Conjunctivitis (6.3%) Arthralgia (12.5%) Application site reaction (31.3%) Photophobia (18.8%) Dehydration (6.3%) Dysuria (6.3%) Sweating increased (6.3%) |
2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
Other AEs: Headache, Hypoaesthesia... Other AEs: Headache (33.3%) Sources: Hypoaesthesia (0%) Malaise (8.3%) Myalgia (0%) Nausea (16.7%) Pharyngitis (0%) Somnolence (8.3%) Upper respiratory infection (0%) Vomiting (16.7%) Dizziness (8.3%) Abdominal pain (8.3%) Coughing (0%) Diarrhea (0%) Anorexia (8.3%) Flushing (0%) Injection site reaction (0%) Back pain (0%) Dyspepsia (0%) Paraesthesia (8.3%) Renal pain (0%) Rigors (0%) Fatigue (8.3%) Conjunctivitis (0%) Arthralgia (0%) Application site reaction (0%) Photophobia (0%) Dehydration (0%) Dysuria (0%) Sweating increased (0%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Anorexia | 0% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
Coughing | 0% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
Fatigue | 0% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
Hypoaesthesia | 0% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
Malaise | 0% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
Myalgia | 0% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
Nausea | 0% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
Pharyngitis | 0% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
Upper respiratory infection | 0% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
Vomiting | 0% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
Arthralgia | 12.5% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
Dyspepsia | 12.5% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
Flushing | 12.5% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
Injection site reaction | 12.5% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
Rigors | 12.5% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
Photophobia | 18.8% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
Application site reaction | 31.3% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
Headache | 43.8% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
Abdominal pain | 6.3% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
Back pain | 6.3% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
Conjunctivitis | 6.3% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
Dehydration | 6.3% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
Diarrhea | 6.3% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
Dizziness | 6.3% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
Dysuria | 6.3% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
Paraesthesia | 6.3% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
Renal pain | 6.3% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
Somnolence | 6.3% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
Sweating increased | 6.3% | 1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: |
healthy n = 16 Health Status: healthy Population Size: 16 Sources: |
Application site reaction | 0% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
Arthralgia | 0% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
Back pain | 0% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
Conjunctivitis | 0% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
Coughing | 0% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
Dehydration | 0% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
Diarrhea | 0% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
Dyspepsia | 0% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
Dysuria | 0% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
Flushing | 0% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
Hypoaesthesia | 0% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
Injection site reaction | 0% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
Myalgia | 0% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
Pharyngitis | 0% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
Photophobia | 0% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
Renal pain | 0% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
Rigors | 0% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
Sweating increased | 0% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
Upper respiratory infection | 0% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
Nausea | 16.7% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
Vomiting | 16.7% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
Headache | 33.3% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
Abdominal pain | 8.3% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
Anorexia | 8.3% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
Dizziness | 8.3% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
Fatigue | 8.3% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
Malaise | 8.3% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
Paraesthesia | 8.3% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
Somnolence | 8.3% | 2400 mg single, oral Highest studied dose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
healthy n = 12 Health Status: healthy Population Size: 12 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Mesnum as a protector against kidney and bladder toxicity with high-dose ifosfamide treatment. | 1982 |
|
Experience with mesna in patients receiving allogeneic bone marrow transplants for poor prognostic leukaemia. | 1983 Sep |
|
Comparison of mesna with forced diuresis to prevent cyclophosphamide induced haemorrhagic cystitis in marrow transplantation: a prospective randomised study. | 1984 Dec |
|
[Prevention of tumor formation in the bladder by sodium-2-mercaptoethane sulfonate (mesna). Experimental studies and clinical consequences]. | 1984 Sep |
|
Encephalopathy associated with ifosphamide/mesna therapy. | 1985 Feb 16 |
|
Ifosfamide, mesna, and encephalopathy. | 1985 Jun 15 |
|
Ifosfamide/mesa and encephalopathy. | 1985 Mar 30 |
|
Cause and prevention of mafosfamide-induced venous pain. | 1986 |
|
Ifosfamide plus mesna with and without adriamycin in soft tissue sarcoma. | 1986 |
|
CNS-side effects induced by Ifosfamide-Mesna in children with osteosarcomas. | 1986 |
|
Central nervous system toxicity following the treatment of pediatric patients with ifosfamide/mesna. | 1986 Aug |
|
Avoiding ifosfamide/mesna encephalopathy. | 1986 Aug 16 |
|
Prediction of ifosfamide/mesna associated encephalopathy. | 1986 Jul |
|
The protective effect of 2-mercapto-ethane sulfonate (MESNA) on hemorrhagic cystitis induced by high-dose ifosfamide treatment tested by a randomized crossover trial. | 1986 Jun |
|
Phase II study of ifosfamide in cervical cancer. | 1986 Jun |
|
Electron microscopic investigations of the cyclophosphamide-induced lesions of the urinary bladder of the rat and their prevention by mesna. | 1987 |
|
Ifosfamide/mesna encephalopathy. | 1987 Apr 25 |
|
Irreversible encephalopathy with ifosfamide/mesna. | 1987 Aug |
|
Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. | 1987 Aug |
|
Ifosfamide-induced subclinical tubular nephrotoxicity despite mesna. | 1987 Feb |
|
Encephalopathy with rapid infusion ifosfamide/mesna. | 1987 Feb 14 |
|
The efficacy of mesna (2-mercaptoethane sodium sulfonate) as a uroprotectant in patients with hemorrhagic cystitis receiving further oxazaphosphorine chemotherapy. | 1987 May |
|
Efficacy of mesna in preventing further cyclophosphamide-induced hemorrhagic cystitis. | 1988 |
|
Ifosfamide/mesna related encephalopathy: a case report with a possible role of phenobarbital in enhancing neurotoxicity. | 1988 |
|
[Encephalopathy caused by an ifosfamide-mesna combination]. | 1988 Apr 2 |
|
Treatment of gynecological adenocarcinomas with a combination of ifosfamide, adriamycin and cisplatin. | 1988 May |
|
Dana-Farber Cancer Institute studies in advanced sarcoma. | 1990 Feb |
|
Mesna versus hyperhydration for the prevention of cyclophosphamide-induced hemorrhagic cystitis in bone marrow transplantation. | 1991 Nov |
|
Feasibility and efficacy of arginine 2-mercaptoethanesulfonate (ARGIMESNA) in the prevention of hemorragic cystitis from ifosfamide (IFO). | 1992 Apr |
|
Mesna side effects which imitate vasculitis. | 1992 Aug |
|
Response of cyclophosphamide-resistant Wegener's granulomatosis to etoposide. | 1992 Aug 15 |
|
Primary tumour mutant p53 gene protein and epidermal growth factor receptor expression and doxorubicin plus ifosfamide for recurrent breast cancer. | 1992 Mar |
|
Encephalopathy in ifosfamide-treated patients. | 1992 Nov |
|
[Epileptic seizures and treatment with ifosfamide-mesna]. | 1994 |
|
[The prevention of hemorrhagic cystitis during the performance of bone marrow and peripheral blood stem cell transplantation in the hematologic cancer clinic]. | 1996 |
|
Ifosfamide encephalopathy and methylene-blue: a case report. | 1996 Aug |
|
Influence of mesna on urotoxic effects of selected bromosubstituted analogs of ifosfamide. | 1997 |
|
Use of dexamethasone with mesna for the prevention of ifosfamide-induced hemorrhagic cystitis. | 2003 Nov |
|
Pelvic primitive neuroectodermal tumor associated with a cluster of small round cell tumors: case report and review of current literature. | 2003 Oct |
|
Angiogenesis inhibition by angiostatin, endostatin and TNP-470 prevents cyclophosphamide induced cystitis. | 2004 |
|
Hyperbaric oxygen therapy for cyclophosphamide induced refractory hemorrhagic cystitis in a child. | 2004 Aug |
|
Contribution of flavonoid antioxidants to the preventive effect of mesna in cyclophosphamide-induced cystitis in rats. | 2005 Aug |
|
Doxorubicin-induced second degree and complete atrioventricular block. | 2005 May |
|
Comparison of uroprotective efficacy of mesna and amifostine in Cyclophosphamide- induced hemorrhagic cystitis in rats. | 2006 Jan-Mar |
|
Ifosfamide metabolites CAA, 4-OH-Ifo and Ifo-mustard reduce apical phosphate transport by changing NaPi-IIa in OK cells. | 2006 Nov |
|
A 50-year-old man with burkitt lymphoma. | 2008 Oct |
|
Characterization of the occurrence of ifosfamide-induced neurotoxicity with concomitant aprepitant. | 2008 Sep |
|
Increased sensitivity of glutathione S-transferase P-null mice to cyclophosphamide-induced urinary bladder toxicity. | 2009 Nov |
|
Preservation of uroplakins by 2-mercaptoethanesulfonate in cyclophosphamide-induced rat cystitis. | 2011 Jan |
|
Acrolein and chloroacetaldehyde: an examination of the cell and cell-free biomarkers of toxicity. | 2013 Feb 25 |
Name | Type | Language | ||
---|---|---|---|---|
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000180854
Created by
admin on Fri Dec 16 18:51:45 UTC 2022 , Edited by admin on Fri Dec 16 18:51:45 UTC 2022
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
Mercaptoethanesulfonic acid
Created by
admin on Fri Dec 16 18:51:45 UTC 2022 , Edited by admin on Fri Dec 16 18:51:45 UTC 2022
|
PRIMARY | |||
|
VHD28S0H7F
Created by
admin on Fri Dec 16 18:51:45 UTC 2022 , Edited by admin on Fri Dec 16 18:51:45 UTC 2022
|
PRIMARY | |||
|
SUB32737
Created by
admin on Fri Dec 16 18:51:45 UTC 2022 , Edited by admin on Fri Dec 16 18:51:45 UTC 2022
|
PRIMARY | |||
|
VHD28S0H7F
Created by
admin on Fri Dec 16 18:51:45 UTC 2022 , Edited by admin on Fri Dec 16 18:51:45 UTC 2022
|
PRIMARY | |||
|
17905
Created by
admin on Fri Dec 16 18:51:45 UTC 2022 , Edited by admin on Fri Dec 16 18:51:45 UTC 2022
|
PRIMARY | |||
|
58319
Created by
admin on Fri Dec 16 18:51:45 UTC 2022 , Edited by admin on Fri Dec 16 18:51:45 UTC 2022
|
PRIMARY | |||
|
DTXSID8023264
Created by
admin on Fri Dec 16 18:51:45 UTC 2022 , Edited by admin on Fri Dec 16 18:51:45 UTC 2022
|
PRIMARY | |||
|
222-167-0
Created by
admin on Fri Dec 16 18:51:45 UTC 2022 , Edited by admin on Fri Dec 16 18:51:45 UTC 2022
|
PRIMARY | |||
|
598
Created by
admin on Fri Dec 16 18:51:45 UTC 2022 , Edited by admin on Fri Dec 16 18:51:45 UTC 2022
|
PRIMARY | |||
|
3375-50-6
Created by
admin on Fri Dec 16 18:51:45 UTC 2022 , Edited by admin on Fri Dec 16 18:51:45 UTC 2022
|
PRIMARY | |||
|
1546354
Created by
admin on Fri Dec 16 18:51:45 UTC 2022 , Edited by admin on Fri Dec 16 18:51:45 UTC 2022
|
PRIMARY | RxNorm | ||
|
DB09110
Created by
admin on Fri Dec 16 18:51:45 UTC 2022 , Edited by admin on Fri Dec 16 18:51:45 UTC 2022
|
PRIMARY |
METABOLITE (PARENT)
METABOLITE INACTIVE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SUBSTANCE RECORD